Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor-Reference-Cited by-同舟云学术

Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor

Published:2013-06-18 Issue:24 Volume:127 Page:2403-2413
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Tavori Hagai¹,Fan Daping¹,Blakemore John L.¹,Yancey Patricia G.¹,Ding Lei¹,Linton MacRae F.¹,Fazio Sergio¹

Affiliation:

1. From the Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Departments of Medicine (H.T., J.L.B., P.G.Y., L.D., M.F.L., S.F.), Pharmacology (M.F.L.), and Pathology, Microbiology, and Immunology (S.F.), Vanderbilt University Medical Center, Nashville, TN; and Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia (D.F.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference50 articles.

1. National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study

2. SREBPs: Transcriptional Mediators of Lipid Homeostasis

3. Management of Lipids in the Prevention of Cardiovascular Events

4. NARC-1/PCSK9 and Its Natural Mutants

5. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Changes Induced by Bariatric Surgery May be Mediated by PAI-1 and PCSK9 Crosstalk;Archives of Medical Research;2024-07

2. Cholesterol reduction by immunization with a PCSK9 mimic;Cell Reports;2024-06

3. Effect of anti-PCSK9 drugs on the association of PCSK9 to LDL;European Atherosclerosis Journal;2024-04-30

4. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial;The Lancet Diabetes & Endocrinology;2024-03

5. Atherosclerosis and Toll-Like Receptor4 (TLR4), Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1), and Proprotein Convertase Subtilisin/Kexin Type9 (PCSK9);Mediators of Inflammation;2024-02-27